Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Adaptive Design, Multicenter, Parallel Group, Placebo-Controlled, 58 Day, Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome

NCT00630370 is registered in ClinicalTrials.gov with Procter and Gamble as lead sponsor.

NCT NCT00630370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00630370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Adaptive Design, Multicenter, Parallel Group, Placebo-Controlled, 58 Day, Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome
Lead sponsor
Procter and Gamble
Phase
Phase 2
Overall status
Terminated
Start date
February 29, 2008
Completion date
July 31, 2008
Enrollment
6 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

post prandial distress syndrome